European Commission approves Ronapreve to treat non-hospitalised COVID-19 patients
The decision follows one day after the positive opinion by the EMA Committee for CHMP, reflecting the EMA and the European…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Roche
FDA approves Roche’s Susvimo for neovascular or “wet” age-related macular degeneration (nAMD)
Susvimo, previously called Port Delivery System with ranibizumab, is the first nAMD treatment in 15 years to provide an…
US FDA advisers to review Merck’s Molnupiravir soon
The US FDA's panel will meet on 30th November, 2021 to discuss the safety and effectiveness of Molnupiravir for the treatment of…
Roche says Ocrevus drug reduces need for walking aids for MS patients
There was a 35 per cent reduction in the need for a walking aid in patients with relapsing multiple sclerosis (MS) after seven and…
US FDA grants breakthrough therapy designation to Roche’s anti-amyloid beta antibody gantenerumab
Gantenerumab is an investigational antibody in phase-III development for early Alzheimer's disease (AD)
Ronapreve shows positive results in COVID patients
Data from phase II/III 2066 study by Roche show that Ronapreve significantly reduced viral load within seven days of treatment in…
New phase-III data support Roche’s Tecentriq in early-stage lung cancer
As published in The Lancet, Tecentriq is the first and only cancer immunotherapy to demonstrate positive phase-III results in the…
Hetero gets emergency use nod to make Roche’s COVID-19 drug
Hetero expects to make the treatment, tocilizumab, available in India by the end of the month under the brand name Tocira
US FDA grants priority review to Roche’s Tecentriq as adjuvant treatment for non-small cell lung…
Tecentriq is the first and only cancer immunotherapy to demonstrate positive phase-III results in the adjuvant lung cancer setting…
FDA accepts application for Roche’s Faricimab
If approved, Faricimab would be the first and only medicine designed to target two distinct pathways that drive retinal diseases…